400+
Engaged Patients
30+
Dedicated Researchers
15+
Myeloma Centers of Excellence
10+
Years of Impact
ACTIVE RESEARCH
MASTER-2 Trial
The MASTER-2 trial pioneers the use of measurable residual disease (MRD) to modulate type and intensity of therapy for patients with newly diagnosed multiple myeloma. This trial studies deferral of transplantation for patients who achieve MRD negativity, the use of an anti-BCMA bispecific T-cell engager for patients MRD positive, and MRD-guided fixed duration therapy.
Publications
Longer follow up of the MASTER trial shows the outcomes of patients who achieved MRD negativity and discontinued therapy.
A panel of CoMMit experts put together a number of practical recommendations to reduce the impact of infections in the outcomes of patients with MM receiving bispecific antibodies or CAR T-cells.
Using data from MASTER enriched by a real-world dataset, we used rigorousn methodology to determine the best MRD endpoint for treatment cessation in NDMM.
By running clinical trials with limited duration of therapy, we could describe the patterns of immune reconstitution after treatment cessation.
We used next-generation sequencing to quantify myeloma disease burden before and after autologous stem cell transplantations providing a benchmark to study immunotherapeutic alternatives to transplantation.
Using data from MASTER enriched by a real-world dataset we framed the concept of “MRD-P”, the increase in MRD burden without traditional criteria for progression and describe its prognostic implication.
